Merck (MRK) Stock Forecast & Price Target

Merck & Co is well positioned by its diversified human health franchise, with Keytruda, Gardasil, Winrevair, and Ohtuvayre driving a sales mix that includes 53% from US human health in 2025, while vaccines and animal health add resilience. The positive outlook rests on evidence that newer assets are scaling and the pipeline is de-risking: 3Q 2026 sales of $18.09 billion and EPS of $2.49 beat expectations, and ESMO data strengthened confidence in sac-TMT and intismeran while supporting multiple upcoming catalysts. That combination of stronger commercialization, late-stage readouts, and potential M&A to offset Keytruda’s 2028 LOE supports faster ex-Keytruda growth and a higher long-term earnings profile.

Merck & Co is viewed negatively because its 2027 growth profile looks constrained by looming loss-of-exclusivity headwinds from legacy products such as Bridion, Januvia/Janumet, and Adempas, while new growth drivers like Winrevair, Welireg, and Capvaxive are not expected to fully offset the gap. Management’s signaling of 2027 as a strategic investment year, with elevated R&D and higher SG&A, implies muted EPS, with estimates cut to $8.55 from $8.83 and sales growth modeled at only 2.4% versus Street expectations of 5%. The stock also faces valuation and durability risk as Keytruda growth decelerates ahead of the 2028 patent cliff, German pricing pressure intensifies, and execution across the pipeline remains critical amid a premium 17.1x 2027E EPS multiple.